ClinicalTrials.gg
CompletedNCT01511003TREASUREUpdated Aug 13, 2018

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

A Phase 4 interventional study of Tacrolimus in Rheumatoid Arthritis, sponsored by Astellas Pharma Inc. Completed at 4 sites in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-13.

Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Arthritis, Rheumatoid by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Arthritis, Rheumatoid · Astellas Pharma Inc.

Enrollment
13th of 29
128 · median 86
Started
2011
with 6 others
Phase 4
5 of 32
none open now
Registered
12th of 32
by date

Among the 32 studies in Arthritis, Rheumatoid by Astellas Pharma Inc, this one is the 13th largest by enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2011, is one of 5 in phase 4, and was the 12th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 32 studies in Arthritis, Rheumatoid by Astellas Pharma Inc is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in Arthritis, Rheumatoid by Astellas Pharma Inc as a file.
02

Study summary

This study is to assess efficacy and safety of tacrolimus in active rheumatoid arthritis patients who showed unsuccessful response to existing DMARDs.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • calcineurin inhibitor
  • Prograf
  • Rheumatoid arthritis (RA)
  • Tacrolimus
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have rheumatoid arthritis for 6 months or longer based on American College of Rheumatology (ACR) diagnostic criteria
  • Subjects who used more than 1 Disease Modifying Antirheumatic Drug (DMARD) including MTX (methotrexate) for 6 months or longer
  • Subjects with ESR (erythrocyte sedimentation rate) ≥ 28mm/h or CRP (C-reactive protein)≥ 1.0 mg/dL
  • Subjects with ≥ 3 swollen joints out of 66 joints assessed
  • Subjects with ≥ 6 tender joints out of 68 joints assessed

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women, or subjects who plan to become pregnant within 6 months or whose screening test results show pregnancy cannot be ruled out
  • Subjects with previous experience of tacrolimus (excluding external preparations)
  • Subjects with renal dysfunction or with serum creatinin > 1.4 mg/dL at screening
  • Following subjects with hepatic dysfunction: viral infection, non-viral infection, hepatic cirrhosis, and Serum Glutamic Oxaloacetic Transaminase / Serum Glutamic Pyruvic Transaminase (/SGPT) exceeding twice the at screening
  • Subjects with pancreatitis, uncontrolled diabetes or complication(s) or with > 6.4% at screening
  • Subjects complicated with hyperkalemia or with serum potassium level >5.5 mEq/L at screening
  • Subjects with history of heart disease (ischemic heart disease, arrhythmia requiring treatment, and heart failure), etc or complications
  • Subjects complicated with severe respiratory disease and infection
  • Subjects with history of malignant tumor or complication(s) (However, the subjects who are considered to have no risk of recurrence with malignant tumor untreated for 5 years or longer can enter the study. The subjects who succeeded in treatment for basal cell or squamous cell carcinoma of skin can also enter the study.)
  • Subjects who were treated with other product(s) within 3 months before screening
  • Other subjects who are considered ineligible for the study by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Tacrolimus group

    oral

    Drug: Tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. ACR20 response rate 6 months post dose

    ACR20 is 20% improvement in ACR (American College of Rheumatology) core set

    Time frame: Baseline and 6 months post dose

Secondary outcomes

  1. ACR50 response rates at month 6

    ACR50 is 50% improvement in ACR (American College of Rheumatology) core set

    Time frame: Baseline and at month 6

  2. ACR70 response rates at month 6

    ACR70 is 70% improvement in ACR (American College of Rheumatology) core set

    Time frame: Baseline and at month 6

  3. Change in DAS28 from baseline to 6 months

    DAS (Disease Activity Score in Rheumatoid Arthritis)

    Time frame: Baseline and at month 6

  4. Change in bone loss rate from baseline to 6 months

    comparative factors for bone loss rate: bone mineral densitometry \[BMD\], bone turnover marker test

    Time frame: Baseline and at month 6

  5. Safety assessed by the incidence of adverse events, vital signs and lab-tests

    Time frame: For 6 months

07

Study locations

4 sites
  • Busan, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Gyeonggi-do, Korea, Republic of
  • Seoul, Korea, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in May 2015, 41 months.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 41 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2012
First posted
Jan 18, 2012
StartActual
Dec 5, 2011
Primary completionActual
May 11, 2015
CompletionActual
May 11, 2015
Last update
Aug 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01511003
Responsible party
Sponsor
First posted
Jan 18, 2012
Start date
Dec 5, 2011
Primary completion
May 11, 2015
Completion
May 11, 2015
Last update
Aug 13, 2018

Study contacts

Use Central Contact
study chair · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion